

# The role of anti-mullerian hormone in determining ovarian reserve in patients with endometrioma and benign cysts

 <sup>1</sup>Ergül DEMİRÇİVİ  
 <sup>2</sup>Duygu VARDAĞLI  
 <sup>3</sup>Ali İsmet TEKİRDAĞ  
 <sup>3</sup>Özgür AKBAYIR  
 <sup>3</sup>Ahmet GÜLKILIK  
 <sup>4</sup>Beyhan ÖMER  
 <sup>5</sup>Sezai ŞAHMAY

<sup>1</sup>Department of Obstetrics and Gynecology, Istanbul Medeniyet University, Istanbul, Turkey

<sup>2</sup>Division of Health Service Vocational School, Istanbul Esenyurt University, Istanbul, Turkey

<sup>3</sup>Department of Obstetrics and Gynecology, Istanbul Kanuni Sultan Suleyman Training and Research Hospital, Istanbul, Turkey

<sup>4</sup>Department of Biochemistry, Istanbul University Faculty of Medicine, Istanbul, Turkey

<sup>5</sup>Department of Obstetrics and Gynecology, Istanbul University Cerrahpasa Faculty of Medicine, Istanbul, Turkey

## ORCID ID

ED : 0000-0002-4448-3863  
DV : 0000-0002-9022-1338  
AİT : 0000-0002-0076-4815  
ÖA : 0000-0002-2699-4969  
AG : 0000-0002-9403-592X  
BÖ : 0000-0001-7938-6281  
SŞ : 0000-0001-9363-5360



## ABSTRACT

**Objective:** Our aim was to determine the effects of endometrioma by itself and its surgery on ovarian reserve via pre- and postoperative serial measurements of Anti-Mullerian Hormone (AMH) in patients with endometrioma and benign cysts.

**Material and Methods:** Our study was conducted at an education and research hospital as a prospective controlled clinical trial. Participants were divided according to their diagnosis into endometrioma and non-endometrioma groups. Serial blood samples of the patients for serum AMH levels were collected preoperatively, and postoperatively at the first week, first month, and third month, respectively.

**Results:** A total of 46 patients (25 for the study and 21 for control groups) were included in the study. The mean age of our patients was  $31.8 \pm 5.57$  in the endometrioma group and  $29.38 \pm 8.64$  in the control group. The AMH value was lower in the endometrioma group, but the difference did not reach statistical significance ( $p > 0.05$ ). However, in the postoperative AMH levels measured at the 1<sup>st</sup> week, 1<sup>st</sup> month, and 1<sup>st</sup> year, the values were significantly higher in the non-endometrioma group compared to the endometrioma group ( $p < 0.05$ ).

**Conclusion:** According to our study, we can conclude that endometrioma surgery affects ovarian reserve significantly and more negatively than benign cystectomies.

**Keywords:** Anti-mullerian hormone (AMH), benign cyst, endometrioma, ovarian reserve, surgery.

**Cite this article as:** Demirçivi E, Vardağlı D, Tekirdağ Aİ, Akbayır Ö, Gülkılık A, Ömer B, Şahmay S. The role of anti-mullerian hormone in determining ovarian reserve in patients with endometrioma and benign cysts. Zeynep Kamil Med J 2024;55(1):29–33.

**Received:** June 14, 2023 **Revised:** July 15, 2023 **Accepted:** August 21, 2023 **Online:** February 27, 2024

**Correspondence:** Ergül DEMİRÇİVİ, MD. İstanbul Medeniyet Üniversitesi, Kadın Hastalıkları ve Doğum Anabilim Dalı, İstanbul, Türkiye.

**Tel:** +90 216 566 40 00 **e-mail:** drergul@yahoo.com

Zeynep Kamil Medical Journal published by Kare Publishing. Zeynep Kamil Tıp Dergisi, Kare Yayıncılık tarafından basılmıştır.

**OPEN ACCESS** This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).



## INTRODUCTION

Endometriosis affects approximately 10% of women of reproductive age.<sup>[1]</sup> It is most commonly found in pelvic organs such as the peritoneum, ovary, or recto-vaginal septum.<sup>[2]</sup> Ovarian endometrioma may originate from endometriotic peritoneal implants on the ovarian surface<sup>[3]</sup> or from metaplasia of ovarian surface epithelium invaginations.<sup>[4]</sup> Primordial follicles in the ovarian cortex constitute the ovarian reserve,<sup>[5]</sup> and endometrioma can affect the ovarian reserve either by itself or through the damage caused to the ovarian cortex during surgical treatment. Various clinical tests are available to estimate ovarian reserve. Serum follicle-stimulating hormone (FSH) and estradiol in the follicular phase have been used as markers for ovarian reserve, but their reliability is limited.<sup>[6]</sup> Recently, anti-Mullerian hormone (AMH), which is produced by granulosa cells of preantral and antral follicles in a gonadotropin-independent period, has started to be used for more precise determination of ovarian reserve.<sup>[7,8]</sup> In our study, we aimed to determine the effect of endometrioma and its surgery on ovarian reserve through pre- and postoperative serial measurements of anti-Mullerian hormone in patients with endometrioma and benign cysts.

## MATERIAL AND METHODS

Our study was conducted at an education and research hospital between 2012 and 2014. A total of 46 patients were included in the study and they were divided into two groups: the endometrioma group (n=25) and the non-endometrioma group (n=21). All patients were symptomatic, complaining of pain due to their endometriomas and benign cysts, and needed surgery. Our inclusion criteria for the study groups were patients who had cysts >4 cm (study group as endometrioma and for the control group as a hemorrhagic or simple cyst) and who were aged between 18–40 years. The exclusion criteria were patients with polycystic ovary syndrome (PCOS), a history of ovarian surgery, a malignancy or borderline ovarian tumor diagnosis after histological examination, endocrinological disorders (thyroid dysfunction, pituitary or adrenal disorders), or oral contraceptive or gonadotropin analog usage in the 3 months prior to surgery.

First, we examined all patients with serial ultrasonography, then collected blood samples for CA125, FSH, luteinizing hormone (LH), estradiol (E2), prolactin (PRL), and AMH (AMH Gen II ELISA, Beckman Coulter Life Sciences, Indiana, USA) during the proliferative phase of the cycle. Additionally, to determine serial serum AMH levels of the patients, their blood samples were collected at the first week, first month, and third month postoperatively. All blood samples were stored at -80 °C until biochemical measurements. For all patients, the ovarian surgery (cystectomy) procedures were done by the same surgery team through laparoscopy or laparotomy (for patients who failed the laparoscopic approach). Every patient's tissue samples were sent for histopathologic examination, and all results were confirmed with the preoperative diagnosis (endometrioma or benign cyst such as serous, mucinous, or corpus luteum cyst).

Statistical analysis was conducted with NCSS (Number Cruncher Statistical System) 2007 Statistical Software (Utah,

**Table 1: Clinical and ultrasonographic data and p values between groups**

|                    | Endometrioma<br>group<br>(n=25)<br>(Mean±SD) | Non-endometrioma<br>group<br>(n=21)<br>(Mean±SD) | p     |
|--------------------|--|--|-------|
| Age                | 31.8±5.57                                    | 29.38±8.64                                       | 0.258 |
| BMI                | 20.92±1.29                                   | 20.95±1.4  | 0.935 |
| Cyst diameter (cm) | 5.16±1.49                                    | 5.57±1.17  | 0.310 |

SD: Standard deviation; BMI: Body mass index.

**Table 2: Obstetric data and p values between groups**

|                   | Endometrioma<br>group<br>(n=25) | Non-endometrioma<br>group<br>(n=21) | p     |
|-------------------|---------------------------------|-------------------------------------|-------|
| Gravidity         |                                 |                                     | 0.715 |
| Mean±SD           | 1.35±1.34                       | 1.53±1.81                           |       |
| Median (IQR)      | 1 (0–2)                         | 1 (0–3)                             |       |
| Parity            |                                 |                                     | 0.659 |
| Mean±SD           | 1±1                             | 1.16±1.3                            |       |
| Median (IQR)      | 1 (0–2)                         | 1 (0–2)                             |       |
| Abortus           |                                 |                                     | 0.806 |
| Mean±SD           | 0.13±0.34                       | 0.16±0.38                           |       |
| Median (IQR)      | 0 (0–0)                         | 0 (0–0)                             |       |
| Ectopic pregnancy |                                 |                                     | 0.370 |
| Mean±SD           | 0.04±0.21                       | 0±0                                 |       |
| Median (IQR)      | 0 (0–0)                         | 0 (0–0)                             |       |

SD: Standard deviation; IQR: Interquartile range.

USA) program. Descriptive statistical methods, Friedman test for nonparametric variables, Mann-Whitney U test for the comparison of nonparametric double groups, Student's t-test for the comparison of parametric double groups, and Chi-square test with Fisher's exact test for the comparison of variables were used for statistical analysis. We considered p-values <0.05 as statistically significant.

## Ethical Aspects

The feasibility and suitability of the prospective controlled study were approved by the local ethics committee (approval date and number: 2011-84/2011-10-11) and registered on the clinical trial website (NCT01982526). The study was conducted in compliance with the Declaration of Helsinki, and written informed consent was obtained from all participating patients.

**Table 3: Group division by cyst laterality and operation type, p values between groups**

|                | Endometrioma group |        | Non-endometrioma group |        | p     |
|----------------|--------------------|--------|------------------------|--------|-------|
| Laterality     |                    |        |                        |        |       |
| Bilateral      | 6                  | 24.00% | 2                      | 9.52%  | 0.268 |
| Right          | 9                  | 36.00% | 12                     | 57.14% |       |
| Left           | 10                 | 40.00% | 7                      | 33.33% |       |
| Operation type |                    |        |                        |        |       |
| Laparotomy     | 13                 | 52.00% | 5                      | 23.81% | 0.072 |
| Laparoscopy    | 12                 | 48.00% | 16                     | 76.19% |       |

**Table 4: Preoperative hormone profile and Ca 125 levels of groups and p values between groups**

|              | Endometrioma group<br>(n=25) | Non-endometrioma group<br>(n=21) | p             |
|--------------|------------------------------|----------------------------------|---------------|
| FSH          |                              |                                  | 0.429         |
| Mean±SD      | 6.87±2.35                    | 6.21±2.59                        |               |
| Median (IQR) | 6.9 (4.79–8.25)              | 6.5 (3.7–8.4)                    |               |
| LH           |                              |                                  | 0.635         |
| Mean±SD      | 6.06±3.45                    | 5.32±2.69                        |               |
| Median (IQR) | 5.33 (3.55–8.8)              | 5.2 (3.1–6.8)                    |               |
| E2           |                              |                                  | 0.501         |
| Mean±SD      | 100.44±87.7                  | 107.27±78.34                     |               |
| Median (IQR) | 68 (54.5–97.5)               | 75 (61–150)                      |               |
| PRL          |                              |                                  | 0.258         |
| Mean±SD      | 13.86±3.6                    | 16.73±6.37                       |               |
| Median (IQR) | 13 (11–15.75)                | 15 (12–22)                       |               |
| CA125        |                              |                                  | <b>0.0001</b> |
| Mean±SD      | 56.76±38.35                  | 22.56±28.36                      |               |
| Median (IQR) | 44 (28–79)                   | 14.5 (7.5–22.5)                  |               |

FSH: Follicle-stimulating hormone; LH: Luteinizing hormone; E2: Estradiol; PRL: Prolactin; SD: Standard deviation; IQR: Interquartile range.

## RESULTS

The total number of patients included in our study, comprising the study group (patients with endometrioma) and the control group (patients with other benign cysts), was 46. However, during the postoperative period, we were unable to follow up with some patients from both the study and control groups due to difficulties in contacting them.

Clinical and ultrasonographic findings, as well as obstetric data, were reported in Tables 1 and 2. Cyst laterality and operation type were also investigated between the two groups (Table 3). There was no statistical significance between the two groups.

**Table 5: P values for AMH results between groups**

| AMH                          | Endometrioma group | Non-endometrioma group | p            |
|------------------------------|--------------------|------------------------|--------------|
| Preop                        |                    |                        | 0.213        |
| Patient numbers              | 25                 | 21                     |              |
| Mean±SD                      | 1.45±1.55          | 2.12±1.72              |              |
| Median (IQR)                 | 0.91 (0.59–1.62)   | 1.5 (0.57–3.88)        |              |
| Postop 1 <sup>st</sup> week  |                    |                        | <b>0.013</b> |
| Patient numbers              | 18                 | 17                     |              |
| Mean±SD                      | 0.93±0.86          | 2.03±1.64              |              |
| Median (IQR)                 | 0.79 (0.29–0.99)   | 1.12 (0.93–3.69)       |              |
| Postop 1 <sup>st</sup> month |                    |                        | <b>0.020</b> |
| Patient numbers              | 9                  | 11                     |              |
| Mean±SD                      | 0.87±0.16          | 2.09±1.83              |              |
| Median (IQR)                 | 0.85 (0.76–0.93)   | 1.19 (1–4.5)           |              |
| Postop 3 <sup>rd</sup> month |                    |                        | <b>0.022</b> |
| Patient numbers              | 6                  | 7                      |              |
| Mean±SD                      | 0.87±0.13          | 3.03±2.62              |              |
| Median (IQR)                 | 0.84 (0.75–1)      | 1.18 (0.98–6.3)        |              |

AMH: Anti-mullerian hormone; SD: Standard deviation; IQR: Interquartile range.

In Table 4, preoperative hormone profiles and CA125 median values were compared between groups, and only the CA125 value of the endometrioma group was significantly higher than that of the non-endometrioma group ( $p=0.0001$ ).

When investigating AMH values between the study and control groups, we found no significant difference in preoperative values. However, postoperative AMH values were significantly higher in the non-endometrioma group than in the endometrioma group at the 1<sup>st</sup> week ( $p=0.013$ ), 1<sup>st</sup> month ( $p=0.02$ ), and 3<sup>rd</sup> month ( $p=0.02$ ) (Table 5). Preoperatively, the mean AMH value of the endometrioma group was lower than that of the non-endometrioma group.

In other words, when analyzing AMH measurements over time within each group, we found no difference (Table 6).

**Table 6: P values between each AMH measurement time matches for both groups**

|  | NEG   | EG    |
|--|-------|-------|
| AMH postop 1 <sup>st</sup> week - AMH preop                        | 0.332 | 0.102 |
| AMH postop 1 <sup>st</sup> month - AMH preop                       | 0.213 | 0.441 |
| AMH postop 3 <sup>rd</sup> month - AMH preop                       | 0.612 | 0.249 |
| AMH postop 1 <sup>st</sup> month - AMH postop 1 <sup>st</sup> week | 0.859 | 0.139 |
| AMH postop 3 <sup>rd</sup> month - AMH postop 1 <sup>st</sup> week | 0.998 | 0.173 |
| AMH postop 3 <sup>rd</sup> month - AMH postop 1 <sup>st</sup> week | 0.998 | 0.686 |

AMH: Anti-mullerian hormone; NEG: Non-endometrioma group; EG: Endometrioma group.

## DISCUSSION

The aim of our study was to address the question: Does endometrioma affect ovarian reserve independently? We can affirmatively respond 'Yes,' as AMH levels were lower among patients in the endometrioma group compared to the control group, although the difference was not significant, possibly due to the small number of patients in each group. The second question was: Does endometrioma surgery affect ovarian reserve? Here, we confidently say 'YES,' as we demonstrated a significant decline in AMH levels after endometrioma surgery compared to the decline observed after surgeries in the control group.

The age-related decrease in AMH, as reported in a recent paper by Yu Wang et al.,<sup>[9]</sup> is already well-documented. Moreover, cyst size and laterality did not affect the AMH levels of endometrioma patients in the same study. However, a study by Karadağ et al.<sup>[10]</sup> showed that AMH levels were negatively correlated with cyst size. On the other hand, AMH levels were not affected by the laterality of the endometrioma in the study by Salihoğlu et al.,<sup>[11]</sup> but Niewegłowska et al.<sup>[12]</sup> found significantly decreased AMH levels in the bilateral endometrioma group compared to the unilateral group. In our study, we used age-matched groups to control for the effect of age on AMH levels and found no significant difference in size or laterality between the endometrioma and control (non-endometrioma) groups.

According to a recent meta-analysis, preoperative AMH levels were noticeably lower in the endometrioma group compared to the control group (including both healthy ovarian tissue and benign cyst groups).<sup>[13]</sup> We also observed a decline in AMH levels in the endometrioma group compared to the non-endometrioma group, but the difference was not statistically significant between groups, possibly due to the small number of patients in each group.

Surgical excision of endometriomas (cystectomy) is currently considered the standard treatment for pain relief.<sup>[14]</sup> However, cystectomy for endometrioma has a detrimental effect on ovarian reserve, which is reflected by a decline in AMH levels following the operation.<sup>[15,16]</sup>

The postoperative decline of AMH levels in endometrioma was proven by considering the pre- and postoperative results of only endometrioma groups in most studies. There are few studies that also

include control (non-endometrioma) group results for pre- and postoperative AMH levels and assess if there are significant differences in or between groups.

In our study, we found significant differences between the endometrioma and non-endometrioma groups for postoperative AMH levels at the 1<sup>st</sup> week, 1<sup>st</sup> month, and 3<sup>rd</sup> month. However, within each group, we could not find any significant change in AMH measurements at different times. The non-significant AMH change between pre- and postoperative periods for both groups was surprising for us, given the literature consensus about postoperative AMH decline after ovarian surgery, especially for endometrioma. Nonetheless, we observed a postoperative AMH decline in both groups. We believe the small group sizes were a limitation of our study for statistically significant findings. However, our results strongly suggest that endometrioma surgery affects the ovaries more negatively than surgeries for other benign cysts. In the study by Chun et al.,<sup>[17]</sup> there was a significant postoperative AMH decrease in the endometrioma group when compared with the benign cyst group, as in our study, but there was no significant difference between the endometrioma and mature cystic teratoma groups. Also, in the same study, there was no significant preoperative difference in AMH levels between groups. Conversely, another study mentioned that the decline in AMH levels after surgery was similar between the endometrioma and benign ovarian cyst groups.<sup>[18]</sup>

This study contributes to the literature by suggesting that ovarian surgery for endometrioma may negatively affect ovarian reserve. However, as mentioned, the limitation of our study was the small group sizes.

## CONCLUSION

Numerous studies have examined endometrioma and its surgical treatment, with most comparing AMH levels in the same patients before and after ovarian surgery. However, our investigation focused on the impact of surgery for both endometrioma and other cysts on ovarian reserve. In conclusion, there is a need for meta-analyses or reviews comparing pre- and postoperative AMH changes between endometrioma and other ovarian cyst groups to clarify the conflicting results of existing studies.

## Statement

**Ethics Committee Approval:** The Bakırköy Sadi Konuk Training and Research Hospital Clinical Research Ethics Committee granted approval for this study (date: 26.09.2011, number: 2011-10-11).

**Author Contributions:** Concept – ED, AG; Design – ED, SŞ; Supervision – ED, ÖA, AİT; Resource – ED; Materials – ED, DV; Data Collection and/or Processing – ED, BÖ; Analysis and/or Interpretation – ED, AİT; Literature Search – ED, SŞ; Writing – ED, DV, AİT, ÖA, AG, BÖ, SŞ; Critical Reviews – ED, DV, AİT, ÖA, AG, BÖ, SŞ.

**Conflict of Interest:** The authors have no conflict of interest to declare.

**Informed Consent:** Written informed consent was obtained from patients who participated in this study.

**Use of AI for Writing Assistance:** Not declared.

**Financial Disclosure:** The authors declared that this study has received no financial support.

**Peer-review:** Externally peer-reviewed.

## REFERENCES

1. Shafrir AL, Farland LV, Shah DK, Harris HR, Kvaskoff M, Zondervan K, et al. Risk for and consequences of endometriosis: A critical epidemiologic review. *Best Pract Res Clin Obstet Gynaecol* 2018;51:1–15.
2. Nisolle M, Donnez J. Peritoneal endometriosis, ovarian endometriosis, and adenomyotic nodules of the rectovaginal septum are three different entities. *Fertil Steril* 1997;68:585–96.
3. Brosens I, Gordts S, Puttemans P, Benagiano G. Pathophysiology proposed as the basis for modern management of the ovarian endometrioma. *Reprod Biomed Online* 2014;28:232–8.
4. Donnez J, Nisolle M, Gillet N, Smets M, Bassil S, Casanas-Roux F. Large ovarian endometriomas. *Hum Reprod* 1996;11:641–6.
5. Lass A, Silye R, Abrams DC, Krausz T, Hovatta O, Margara R, et al. Follicular density in ovarian biopsy of infertile women: A novel method to assess ovarian reserve. *Hum Reprod* 1997;12:1028–31.
6. Bancsi LF, Broekmans FJ, Mol BW, Habbema JD, te Velde ER. Performance of basal follicle-stimulating hormone in the prediction of poor ovarian response and failure to become pregnant after in vitro fertilization: A meta-analysis. *Fertil Steril* 2003;79:1091–100.
7. Visser JA, Themmen AP. Anti-Müllerian hormone and folliculogenesis. *Mol Cell Endocrinol* 2005;234:81–6.
8. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-Müllerian hormone expression pattern in the human ovary: Potential implications for initial and cyclic follicle recruitment. *Mol Hum Reprod* 2004;10:77–83.
9. Wang Y, Ruan X, Lu D, Sheng J, Mueck AO. Effect of laparoscopic endometrioma cystectomy on anti-Müllerian hormone (AMH) levels. *Gynecol Endocrinol* 2019;35:494–7.
10. Karadag C, Yoldemir T, Demircan Karadağ S, Turgut A. The effects of endometrioma size and bilaterality on ovarian reserve. *J Obstet Gynaecol* 2020;40:531–6.
11. Salihoglu KN, Dilbaz B, Cırık DA, Ozenci R, Ozkaya E, Mollamahmutoglu L. Short-term impact of laparoscopic cystectomy on ovarian reserve tests in bilateral and unilateral endometriotic and nonendometriotic cysts. *J Minim Invasive Gynecol* 2016;23:719–25.
12. Nieweglowska D, Hajdyla-Banas I, Pitynski K, Banas T, Grabowska O, Juszczyk G, et al. Age-related trends in anti-Müllerian hormone serum level in women with unilateral and bilateral ovarian endometriomas prior to surgery. *Reprod Biol Endocrinol* 2015;13:128.
13. Muzii L, Di Tucci C, Di Feliciano M, Galati G, Di Donato V, Musella A, et al. Antimüllerian hormone is reduced in the presence of ovarian endometriomas: A systematic review and meta-analysis. *Fertil Steril* 2018;110:932–40.e1.
14. Dunselman GA, Vermeulen N, Becker C, Calhaz-Jorge C, D'Hooghe T, De Bie B, et al. ESHRE guideline: Management of women with endometriosis. *Hum Reprod* 2014;29:400–12.
15. Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: A systematic review and meta-analysis. *J Clin Endocrinol Metab* 2012;97:3146–54.
16. Younis JS, Shapso N, Fleming R, Ben-Shlomo I, Izhaki I. Impact of unilateral versus bilateral ovarian endometriotic cystectomy on ovarian reserve: A systematic review and meta-analysis. *Hum Reprod Update* 2019;25:375–91.
17. Chun S, Cho HJ, Ji YI. Comparison of early postoperative decline of serum antiMüllerian hormone levels after unilateral laparoscopic ovarian cystectomy between patients categorized according to histologic diagnosis. *Taiwan J Obstet Gynecol* 2016;55:641–5.
18. Kwon SK, Kim SH, Yun SC, Kim DY, Chae HD, Kim CH, et al. Decline of serum antimüllerian hormone levels after laparoscopic ovarian cystectomy in endometrioma and other benign cysts: A prospective cohort study. *Fertil Steril* 2014;101:435–41.